Pacific Biosciences Of California (PACB) Net Income towards Common Stockholders (2010 - 2026)

Pacific Biosciences Of California's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 98.06% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$128.6 million, a 80.45% increase from a year earlier, with the FY2025 full-year figure at -$546.4 million, down 76.34% from the prior year.
• Net Income towards Common Stockholders grew to -$8.3 million in Q1 2026 per PACB's latest filing, from -$40.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $2.4 million in Q4 2024 and bottomed at -$426.1 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$71.4 million (2022), against an average of -$87.4 million.
• Across the five-year window, Net Income towards Common Stockholders soared 102.89% in 2024 and tumbled 1802.7% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$84.4 million in 2022, then advanced by 2.8% to -$82.0 million in 2023, then surged by 102.89% to $2.4 million in 2024, then tumbled by 1802.7% to -$40.4 million in 2025, then surged by 79.5% to -$8.3 million in 2026.
• Per Business Quant, the three latest PACB Net Income towards Common Stockholders figures stand at -$8.3 million (Q1 2026), -$40.4 million (Q4 2025), and -$38.0 million (Q3 2025).